Trial Profile
Effect of ruxolitinib on bone marrow microenvironment and inflammatory cytokine levels in myelofibrosis patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 May 2015
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Pharmacodynamics
- 22 May 2015 New trial record